NAVLIN by EVERSANA

READ NOW: NAVLIN Last Week in Review https://ow.ly/KW7150SsPgf This week from NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, drug approvals and more from across the world: Policy: Learn how new criteria could impact market access and treatments like Gilead’s Trodelvy. Pricing & Reimbursement Discover how Vertex’s long-term agreement with NHS England marks a new era for cystic fibrosis treatment availability. HTA: Learn how CSL Behring’s Hemgenix is set to transform the treatment landscape for adults with severe hemophilia B, following NICE’s final draft guidance. Other: Discover how the EMA and HMA are addressing shortages of key GLP-1 receptor agonists like Ozempic, Saxenda, Trulicity, and Victoza. And more... #NAVLIN #CysticFibrosis #HemophiliaBTreatment #MarketAccess #DrugEvaluation

Learn more about NAVLIN by EVERSANA: https://ow.ly/AiVZ50SpYAj Increasingly complex global commercial launches are driving demand for accurate, actionable and easy-to-understand insights at your fingertips – insights that tell you not just what is going right or wrong with your global commercial strategy, but why – and do so early enough to improve the real value of a therapy over its lifecycle. As newly appointed Senior Vice President of Product Development for EVERSANA, Gustav Ando is responding to this unmet industry need by leading the development of world-class pricing, market access, and commercial insights from NAVLIN by EVERSANA’s market-leading data and software, using technology, data, forecasting and AI tools to drive getting pharmaceutical assets to patients around the world faster.

READ NOW: NAVLIN Last Week in Review https://ow.ly/eZG450Sezqf This week from NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, drug approvals and more from across the world: Pricing & Reimbursement: Novo Nordisk braces for a storm of competition in China. Discover how this could reshape the landscape for diabetes and weight loss treatments. HTA: The European Commission takes a step forward in managing conflicts of interest in health technology assessment. Find out what this means for stakeholders. C&G Therapy: A new gene-editing tool promises to revolutionize cell and gene therapies. Learn how Synthego plans to leverage this technology. Industry Deals & Agreements: Western investors are breaking records with their deals with Chinese firms. Uncover the implications of this surge in biotech investment. Drug Approval: The European market is set for a wave of new medicines. Explore what this means for healthcare in the region. COVID-19: Singapore expands its National Vaccination Program with a new COVID-19 vaccine. Find out why this is a game-changer for those who can’t take mRNA vaccines. Conferences: Our team has been busy attending key pharma conferences. Get the inside scoop on the latest discussions around pricing innovation and contracting. And more...

As the 2024 Pharma Pricing Innovation Conference comes to a close, we want to pause to acknowledge one more reason why attendees keep coming back - and one reason you should join us in 2025. Yes, the topics are timely and relevant to their business challenges. Yes, we bring top industry executives to share their knowledge and insights. But one thing we hear over and over again is that attendees value the intimacy of PPIC and the opportunities to network with their industry peers - time to connect, share and learn from one another, both during sessions and after. 2025 PPIC will be an event you don't want to miss. Watch for more details, and we look forward to you joining us next year! #NAVLIN #PPIC

Day 2 of of the Pharma Pricing Innovation Conference (#PPIC) did not disappoint! Attendees were treated to presentations from global industry executives including: • Anita Gandola (Merck KGaA), presenting on China, NRDL and New Launch Dynamics • Jiri Smejkal (Takeda), who delivered a practical application case study on predictive pricing • Caterina Barone (Chiesi), who facilitated a discussion on an approach for loss-of-exclusivity forecasting But that's not all. Watch for a special follow-up on some of the attendees' favorite moments from the conference. #NAVLIN #LossOfExclusivity #PredictivePricing #NRDL

Standing room only on the official Day 1 of the Pharma Pricing Innovation Conference (PPIC)in Basel, Switzerland! Attendees learned and gained valuable insights from a whole host of industry-leading experts including Carlos Moreira of PricewaterhouseCoopers (PWC), Pedro Borga of Amicus Therapeutics and EVERSANA’s own Paolo Correale, just to name a few. During today’s sessions, over 100 attendees engaged in discussions around global market dynamics, pricing excellence, integration of pricing and commercial strategy, rare disease and oncology pricing and implementation of the NAVLIN platform to help industry executives “Innovate, Accelerate, Integrate.” Day 2 looks to be another fantastic day of content and collaboration – stay tuned for more! #raredisease #pricingexcellence #PPIC #NAVLIN

Kicking off NAVLIN’s Pharma Pricing Innovation Conference (PPIC) in Basel! Today’s workshops marked a dynamic start to PPIC 2024, with our interactive sessions and the unveiling of the newest NAVLIN software features. Highlights included: • Tender Wargames Workshop by Gerardo Peccia: Attendees engaged in a realistic tendering simulation, learning to optimize revenue through strategic bidding. Gerardo's tender platform offers comprehensive tools for tender management. • Global Loss of Exclusivity Workshop by Paolo Correale: An in-depth session on preparing for Loss of Ecslusivity, early lifecycle activities and NAVLIN tools for price forecasting. • U.S. Pricing and Reimbursement Review: Essential insights into the U.S. healthcare system, helping European teams navigate and collaborate effectively in the US market. • NAVLIN Generative AI and product tour by Andrew Hanhauser: Hands-on experience with Ask NAVLIN AI and a showcase of new NAVLIN products like IRP Express. • NAVLIN Data and Software Client Sessions: An interactive deep dive into the product roadmap and process improvements. • Special Session by Prof Dr. Reinhard Rychlik: Insightful coverage on German reimbursement, including the 200 million EUR innovation fund and ATMP handling. We're excited to welcome all the rest of the attendees today for more engaging sessions throughout the week! Let's go PPIC 2024! #PPIC2024 #NAVLIN #Innovation #MarketAccess

Available Now: NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, drug approvals and more from across the world. This week: Policy: What’s the secret plan Germany’s Federal Ministry of Health is sticking to despite rejection? Discover the intrigue behind the Medical Research Act. Pricing & Reimbursement: How is Amgen’s Lumykras changing the game for advanced NSCLC patients in Italy? Uncover the story behind its groundbreaking approval. HTA: What does the European Commission’s new draft document mean for health technology assessments? Dive into the details of this pivotal development. Drug Approval: How is Swissmedic revolutionizing access to cancer treatments in Switzerland? Learn about the impact of their collaboration with the FDA’s Project Orbis. COVID-19: Why is the international treaty for future pandemic management facing delays? Explore the complexities and the path forward. Expert Opinion: What insights did Andy Powrie-Smith share at Reuters Pharma Europe 2024? Get the inside scoop on the EU’s pharmaceutical legislation revision. And more... Click through to uncover these fascinating stories in the healthcare sector: https://ow.ly/ku2K50S6HCH

Exciting news from the tech frontier! The 2024 summer release of NAVLIN Price & Access Data includes Ask NAVLIN, a generative AI assistant that features natural language processing for intuitive, AI-driven queries of our pricing database. As simple as starting a conversation, let Ask NAVLIN help you quickly and easily find answers to your price and market access questions. The future of AI-driven solutions is here, and it's looking brighter than ever! LEARN MORE ABOUT THE NAVLIN SUMMER 2024 RELEASE: https://ow.ly/o4ap50S21cy #AI #Innovation #TechNews #NAVLIN

Exciting news from NAVLIN this summer! We're thrilled to announce our latest release, built to accelerate answering your most challenging pricing and access questions. Our release has the most features ever over the full drug pricing and market access lifecycle! Key Highlights: - A new generative AI assistant featuring natural language processing for intuitive queries across access and price database, news, country guides, and HTA documents - Expanded, comprehensive pricing & market access KPI tracking - Enhanced predictive AI capabilities across the pricing landscape - Expanded forecasting and benchmarking from launch through loss-of-exclusivity Ready to experience the future of pricing and access platforms? Sign up for a free trial or schedule a meeting with us today. Let's navigate success together! CHECK OUT WHAT'S NEW: https://ow.ly/RG4N50RUjTt #NAVLIN #AI #PricingStrategy #Innovation #TechNews